Insulin molecular structure
Insulin molecular structure
Approved
🏋️Weight Loss

Insulin

Also known as: Humalog, Novolog, Lantus, Levemir, Tresiba

MW

5808.00 Da

Formula

C257H383N65O77S6

CAS

11061-68-0

Routes

3 routes

Insulin is a 51-amino acid peptide hormone produced by pancreatic beta cells that serves as the master regulator of glucose metabolism and the body's primary anabolic hormone. Consisting of two polypeptide chains (A-chain: 21 amino acids, B-chain: 30 amino acids) connected by two disulfide bonds, insulin was the first protein to have its structure determined (Frederick Sanger, Nobel Prize 1958) and the first therapeutic protein produced by recombinant DNA technology (1982). The discovery of insulin by Banting and Best in 1921 transformed type 1 diabetes from a fatal disease to a manageable condition, representing one of the most important medical breakthroughs of the 20th century. Today, over 500 million people worldwide depend on insulin therapy. Modern insulin analogs have been engineered for ultra-rapid, rapid, intermediate, and long-acting profiles to mimic physiological insulin secretion patterns.

Research Use OnlyFor educational and research purposes only

Research Applications

Type 1 Diabetes (Approved — Essential)

Insulin is essential for survival in type 1 diabetes and remains irreplaceable. Modern management uses multiple daily injections or continuous subcutaneous insulin infusion (pump therapy).

Type 2 Diabetes (Approved)

Used when oral agents and GLP-1RAs fail to achieve glycemic control. Basal insulin (glargine, detemir, degludec) is typically added first, with bolus insulin for advanced disease.

Smart Insulin Research

Glucose-responsive "smart" insulin formulations that automatically adjust activity based on blood glucose levels are in clinical development.

Closed-Loop Artificial Pancreas

Automated insulin delivery systems coupling continuous glucose monitors with insulin pumps represent the frontier of diabetes technology.

Mechanism of Action

Insulin binds to the insulin receptor (IR), a receptor tyrosine kinase, triggering autophosphorylation and recruitment of IRS proteins (IRS-1/2). This activates two major pathways: PI3K/Akt for metabolic effects (GLUT4 translocation, glycogen synthesis, lipogenesis, protein synthesis) and Ras/MAPK for mitogenic effects (cell growth and differentiation). In muscle and adipose tissue, Akt-mediated GLUT4 translocation to the cell surface enables glucose uptake — the primary mechanism of blood glucose reduction.

Biological Pathways

IR/IRS/PI3K/Akt/GLUT4 for glucose uptake. Akt/GSK-3β for glycogen synthesis. Akt/mTOR/p70S6K for protein synthesis. Akt/FOXO for gluconeogenesis suppression. SREBP-1c for lipogenesis. Ras/Raf/MEK/ERK for cell growth.

Dosage Information

Typical dosage ranges for research applications. Always verify with current literature.
Frequency
Varies by type: rapid before meals, long-acting 1-2x daily
Dosage Calculator
Calculate precise peptide dosages based on your reconstitution parameters
Dosage calculation parameters
Vial size in milligrams
Reconstitution volume in milliliters
Body weight input
Recommended dose per kg
mcg/kg
Desired dose input
mcg

Calculation Results

Concentration
2.5 mg/ml
Dose Volume
0.1 ml0.100 ml
Insulin Syringe
10 units
Doses per Vial
2020 doses @ 250 mcg

Syringe Fill Level (100u syringe)

05010010.0uunits
0u10.0 / 100 units (10%)100u

Protocols

No protocols featuring this peptide yet.

Browse All Protocols

Stability & Storage

Insulin must be stored at 2-8°C before opening. In-use insulin pens/vials can be stored at room temperature (up to 30°C) for 28-42 days depending on formulation. Never freeze. Sensitive to extreme heat and agitation. Modern analogs have improved stability profiles. Insulin is a relatively fragile protein requiring careful handling.

Side Effects & Precautions

Hypoglycemia is the most significant risk — severe hypoglycemia can cause seizures, loss of consciousness, and death. Weight gain (2-4 kg) is common with insulin initiation. Injection site lipohypertrophy from repeated injection in same site. Hypokalemia from insulin-mediated potassium shift. Rare allergic reactions. Insulin edema during initial treatment. Peripheral edema.

Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.

Regulatory Status

Approved

FDA-approved (multiple formulations): rapid-acting (lispro, aspart, glulisine), regular, intermediate (NPH), long-acting (glargine, detemir, degludec), ultra-long-acting, and premixed. Available worldwide. On WHO Essential Medicines List. WADA-prohibited unless medically prescribed for diagnosed diabetes.

Research Studies

The Discovery of Insulin

Banting FG, Best CH.

Journal of Laboratory and Clinical Medicine
1922

Insulin Signaling and the Regulation of Glucose Metabolism

Saltiel AR, Kahn CR.

Nature
2001
View Source

Insulin: Understanding its Action in Health and Disease

Wilcox G.

Clinical Biochemist Reviews
2005
View Source
Dosage Calculator
Calculate reconstitution volumes and injection amounts for Insulin.
Explore More
Explore more peptides in the Weight Loss category and related research.